Open main menu

Psychiatrienet β

Difference between revisions of "Paroxetine-moclobemide"

 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
 
| to = moclobemide  
 
| to = moclobemide  
 
| stop =  
 
| stop =  
{{downparox}}
+
{{Generaldecrease25p3d}}
 +
{{7dWashout}}
 
| start =  
 
| start =  
* '''Day 28:''' moclobemide can be started in a normal dosage of 300 mg/day (2 times a day 150 mg).
+
{{MAOIncrease25p}}
 
| caveat =  
 
| caveat =  
 
{{caveSS}}
 
{{caveSS}}
 
|info=
 
|info=
{{review}}
+
{{SSRI14d}}
 
}}
 
}}

Latest revision as of 13:57, 16 June 2016

paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from paroxetine to moclobemide.[1] [2]

Nietinrijdenbord.png Stop paroxetine
  • Decrease with about 25% of original dose every 3 days
  • Stop and wait 7 days for washout
Eenrichtingbord.png Start moclobemide
  • Start at the first day after the washout period with about 25% of target dose.
Letopbord.png Cave
Infobord.png More information
  • The reduction of the SSRI doses in 7-14 days could cause emotional instability, headache and flu-like symptoms. One could extend this period.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.